Organization (Industry)
Lantheus Medical Imaging (United States)
ClinicalTrials.gov lists Lantheus Medical Imaging (United States) as lead sponsor of 30 trials. It has 9 active development programs and 8 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 4 registered with a 2026 start date. The dashed outline is the pace from the 3 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Lantheus Medical Imaging (United States): 30 lead-sponsored trials and 1 legal-entity registration. Part of Lantheus Holdings, Inc..
Disease areas (52)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Coronary Disease | 11 |
| Coronary Artery Disease | 10 |
| Prostatic Neoplasms | 6 |
| Heart Failure | 4 |
| Myocardial Infarction | 4 |
Showing 5 of 52 disease areas.
Trials by start year as sponsor or collaborator (24)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 3 |
| 2024 | 3 |
| 2023 | 2 |
| 2022 | 1 |
| 2021 | 2 |
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 3 |
| 2017 | 4 |
Showing 10 of 24 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (9)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| [68Ga]-LNTH-2401 | Prostatic Neoplasms | Phase 2/3 | 1 |
| 18F-DCFPyL | Kidney Neoplasms | Phase 2/3 | 1 |
| 18F-DCFPyL | Carcinoma, Renal Cell | Phase 2/3 | 1 |
| Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D). | Osteosarcoma | Phase 1/2 | 1 |
| LNTH2403 Phase 1 dose | Sarcoma | Phase 1/2 | 1 |
Showing 5 of 9 active programs.
Approved assets (8)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| DEFINITY | 4 |
| Technetium Tc99m Sestamibi | 4 |
| Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension | 1 |
| Perflutren Lipid Microsphere Injectable Suspension | 1 |
| Piflufolastat F 18 Intravenous Solution [PYLARIFY] | 1 |
Showing 5 of 8 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 2 of 4 hit target (n=4) | 0 of 2 on time (n=2) |
Journals published in (42)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology | 7 |
| Journal of vascular surgery | 6 |
| Radiology | 5 |
| Circulation | 4 |
| European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery | 4 |
Showing 5 of 42 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 68 | 17 | 2025-12-16 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 8 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| LANTHEUS MEDICAL IMAGING, Inc. | N Billerica, US | FDA, Health Canada |
Organization relationships (9)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Syneos Health (United States) | Uses vendor | 2 |
| Mayo Clinic | Co sponsors trial with | 1 |
| Government of the United States of America | Co sponsors trial with | 1 |
| Vanderbilt Health | Co sponsors trial with | 1 |
| University Health Network, Toronto | Co sponsors trial with | 1 |
Showing 5 of 9 relationships.
Latest dated events (137)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-09 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-03-18 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-02-03 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 137 events.
Biomarker capability evidence (72)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| BCR | Trial sponsor | Primary endpoint in a Phase 3 trial |
| FAP | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 72 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.